Your browser doesn't support javascript.
loading
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Moreau, Philippe; Dimopoulos, Meletios A; Richardson, Paul G; Siegel, David S; Cavo, Michele; Corradini, Paolo; Weisel, Katja; Delforge, Michel; O'Gorman, Peter; Song, Kevin; Chen, Christine; Bahlis, Nizar; Oriol, Albert; Hansson, Markus; Kaiser, Martin; Anttila, Pekka; Raymakers, Reinier; Joao, Cristina; Cook, Gordon; Sternas, Lars; Biyukov, Tsvetan; Slaughter, Ana; Hong, Kevin; Herring, Jennifer; Yu, Xin; Zaki, Mohamed; San-Miguel, Jesus.
Afiliação
  • Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
  • Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece.
  • Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Siegel DS; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
  • Cavo M; Bologna University School of Medicine, Bologna, Italy.
  • Corradini P; University of Milano, Fondazione IRCCS Istituto Nazionale de Tumori, Milano, Italy.
  • Weisel K; University Hospital of Tuebingen, Tuebingen, Germany.
  • Delforge M; University Hospital Leuven, Leuven, Belgium.
  • O'Gorman P; Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland.
  • Song K; Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Chen C; Princess Margaret Hospital, Toronto, Ontario, Canada.
  • Bahlis N; Tom Baker Cancer Center, University of Calgary, Calgary, Canada.
  • Oriol A; Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Hansson M; Skane University Hospital, Lund University, Lund, Sweden.
  • Kaiser M; The Royal Marsden Hospital, Surrey, UK.
  • Anttila P; Helsinki University and Helsinki University Hospital Comprehensive Cancer, Helsinki, Finland.
  • Raymakers R; University Medical Center Utrecht, Utrecht, The Netherlands.
  • Joao C; Hemato-Oncology Department, Champalimaud Foundation for the Unknown and Faculdade de Ciências Médicas-NOVA University, Lisbon, Portugal.
  • Cook G; St James's Institute of Oncology, St James's University Hospital, Leeds, UK.
  • Sternas L; Celgene Corporation, Summit, NJ, USA.
  • Biyukov T; Celgene International Sàrl, Boudry, Switzerland.
  • Slaughter A; Celgene International Sàrl, Boudry, Switzerland.
  • Hong K; Celgene Corporation, Summit, NJ, USA.
  • Herring J; Celgene Corporation, Summit, NJ, USA.
  • Yu X; Celgene Corporation, Summit, NJ, USA.
  • Zaki M; Celgene Corporation, Summit, NJ, USA.
  • San-Miguel J; Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
Eur J Haematol ; 99(3): 199-206, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28504846
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article